Herantis Pharma Plc ("Herantis") announced today the initiation of a non-invasive CDNF development program to broaden the application of CDNF in Parkinson`s disease and potentially other ...

In Parkinson’s disease (PD) dopamine (DA) neurons located in the substantia nigra (SN) degenerate and die. Since all current therapies only treat symptoms, we hope to develop novel disease-modifying ...

A research group at the University of Helsinki and its partners have found a promising drug candidate for the treatment of amyotrophic lateral sclerosis (ALS). Cerebral dopamine neurotrophic factor ...

Cerebral dopamine neurotrophic factor CDNF is being tested in phase one and two clinical trials in Finland and Sweden. Cerebral dopamine neurotrophic factor (CDNF) is an unconventional neurotrophic ...

The Medicines Agency of Sweden, MPA, has authorized Herantis Pharma Plc`s ("Herantis") first-in-human clinical study of the company`s investigational product CDNF for the treatment of Parkinson`s ...

* HERANTIS PHARMA OYJ - TOPLINE ANALYSIS CONFIRMS POSITIVE SAFETY AND TOLERABILITY OF CDNF IN ADVANCED-STAGE PARKINSON'S DISEASE PATIENTS, WITH ENCOURAGING BIOLOGICAL RESPONSES AS MEASURED BY PET ...

The Michael J. Fox Foundation for Parkinson's Research (MJFF) has awarded a grant to Academy Professor Mart Saarma, PhD, and his team at the Institute of Biotechnology of the University of Helsinki.

Nanoform (Finland), an innovative nanoparticle medicine enabling company, and Herantis Pharma Plc (Finland), focusing on disease modifying therapies for debilitating neurodegenerative diseases based ...

A research group at the University of Helsinki and its partners have found a promising drug candidate for the treatment of amyotrophic lateral sclerosis (ALS). Cerebral dopamine neurotrophic factor ...

A research group at the University of Helsinki and its partners have found a promising drug candidate for the treatment of amyotrophic lateral sclerosis (ALS). Cerebral dopamine neurotrophic factor ...